What is the primary product described in the Siren Care deck?

The primary product is the Siren Smart Sock, a temperature-sensing wearable designed for diabetic patients. According to Slide 4 and Slide 9, these socks use proprietary smart fabric to monitor foot temperature continuously. This data is then transmitted to a mobile app to detect potential injuries or ulcers before they become severe, as shown on Slide 10.

How does Siren Care justify the market need for smart socks?

Siren Care justifies the need by highlighting the 'staggering financial costs' of diabetic foot complications, which Slide 7 states is $17 billion annually in the U.S. alone. Furthermore, Slide 6 illustrates a direct progression from neuropathy to ulcers and, ultimately, amputations, positioning the socks as a preventative tool that can reduce ulcers by 72% (Slide 8).

Who are the key members of the Siren Care leadership team?

The team is led by CEO Ran Ma, who has a background in Biomedical Engineering from Johns Hopkins University. Other key members include CTO Jie Fu (formerly of Cisco and Philips) and COO Henk Jan Scholten, who specializes in global textile sourcing. The team is supported by a robust board of medical and business advisors, as detailed on Slide 11.

What is missing from the Siren Care pitch deck?

The deck is notably missing several standard venture capital components. There are no slides detailing the business model (subscription vs. hardware sale), no financial projections, no competitive landscape analysis, and no specific 'Ask' regarding the amount of capital being raised or the intended use of funds.

Is Siren Care strictly a healthcare company according to the deck?

While the deck focuses almost entirely on the 'Diabetic Foot Program,' Slide 12 reveals a much broader vision. It describes a 'Siren Eco-System' where their smart textile technology could be applied to fitness, fashion, military, and entertainment sectors, suggesting the company views itself as a platform technology rather than a single-product medical device firm.

Siren Care Pitch Deck (2015): 13-Slide Series B Deck

See all 13 slides of the Siren Care pitch deck — a 2015 Series B deck — with a slide-by-slide teardown of what the deck does well and where it falls short.

Siren Care’s 2015 pitch deck is a textbook example of how to pitch a hardware-enabled service by focusing on a specific, high-cost medical problem. While the company describes itself as a 'Next Generation Smart Textile' platform (Slide 1), the deck spends the majority of its time on the 'Diabetic Foot'—a condition affecting 40% of the 415 million people with diabetes (Slide 5). The deck is visually driven, using stark imagery of medical complications (Slide 6) and clear financial stakes ($17B/year cost to the U.S. healthcare system, Slide 7) to justify its existence. Despite the lack of finan…

Key takeaways

The deck frames the technology as a solution to a 'Global Pandemic' of diabetes, citing 415 million current cases (Slide 5).
It identifies a specific, high-risk niche: the 40% of diabetic patients with severe neuropathy (Slide 5).
The financial burden of the problem is quantified at $17 billion per year for the U.S. healthcare system (Slide 7).
Clinical efficacy is highlighted by stating that temperature monitoring can reduce foot ulcers by 72% (Slide 8).
The product is positioned as 'Made for Manufacturing,' emphasizing scalability and adaptability (Slide 3).
The team slide showcases deep institutional ties, including Johns Hopkins, Philips, and Cisco (Slide 11).
The deck lacks any mention of unit economics, revenue models, or a specific funding request.
The vision expands beyond healthcare into fitness, fashion, military, and entertainment (Slide 12).

The Siren Care Pitch Deck: A Strategic Teardown

Siren Care’s 13-slide deck from 2015 is a study in focused storytelling. At a time when 'wearables' were often dismissed as toys, Siren Care successfully pivoted the conversation toward clinical necessity. By the time this deck was circulating, the company was positioning itself for a Series B, eventually raising $21.9 million to bring its smart textile technology to market. The deck does not rely on complex charts; instead, it uses high-impact imagery and massive macro-economic figures to build a case for a product that is, at its core, a pair of socks.

Introduction and Technology Foundation (Slides 1-3)

Slide 1: Title The deck opens with a minimalist title slide. The tagline, "Next Generation Smart Textiles To Empower People," sets a broad, ambitious tone. The contact information for CEO Ran Ma is visible in the top right corner, a standard but necessary inclusion for investor outreach.

Slide 2: The Vision This slide uses a 'future-casting' approach. It claims that in the "not so distant future," clothes will monitor the body, communicate with the world, and control the environment. This is a classic 'Why Now?' setup, suggesting that the era of passive clothing is ending.

Slide 3: Siren Smart Fabric Here, the company addresses a major concern for hardware investors: manufacturability. By labeling the fabric as "Made For Manufacturing," "Adaptable," and "Scalable," they attempt to de-risk the technical hurdles of integrating electronics into textiles. The claim that this is a "New Industry Standard" is bold, though the slide lacks technical specifications to back it up.

The Problem: The Diabetic Foot (Slides 4-7)

Slide 4: Siren Smart Socks This slide introduces the flagship product: Temperature Sensing Socks. The imagery is domestic and non-threatening, showing a couple relaxing, which emphasizes that the technology "blends into everyday life."

Slide 5: Diabetes - A Global Pandemic The deck shifts from product to market size. It cites 415 million people worldwide with diabetes, projected to grow to 600 million by 2035. Crucially, it narrows the focus to the 40% of patients with "severe Neuropathy." This is a vital distinction—it shows the founders understand their specific high-risk cohort.

Slide 6: The Clinical Progression This is the most visceral slide in the deck. It shows a clear, three-step path: Neuropathy + Arterial Disease leads to Injuries/Ulcers/Gangrene, which leads to Amputations. By showing a bandaged foot, the deck makes the stakes of the problem undeniable. It moves the product from a 'nice-to-have' to a 'must-have' for limb preservation.

Slide 7: Financial Impact For the institutional investor, the human cost must be paired with a financial one. The slide features a stethoscope over stacks of cash with the figure "$17B/YEAR" in bold. This represents the cost to the U.S. healthcare system, suggesting that a preventative tool like Siren Socks could capture a significant portion of this 'wasted' spend through cost savings.

The Solution and Efficacy (Slides 8-10)

Slide 8: Data Can Save Lives This slide provides the 'Proof of Concept.' It states that "Temperature Monitoring Can Reduce Foot Ulcers By 72%." It contrasts the Siren approach with "Temptouch," a manual temperature probe. The implication is that continuous monitoring (Siren) is superior to point-in-time checks.

Slide 9: Product Integration The deck returns to the physical product, showing a close-up of the sock with a small, white circular sensor. The text reiterates that the technology "blends into every day life," addressing potential patient compliance issues—if it looks like a normal sock, patients are more likely to wear it.

Slide 10: The Siren Care App This slide demonstrates the user interface. It shows a heat map of the feet with green, orange, and red indicators. A push notification reads: "Please check your left heel for a sore or injury. And reduce activity in that area." This clarifies the value proposition: the hardware is just the data collector; the software is the intervention tool.

Team and Future Vision (Slides 11-13)

Slide 11: Our Team and Advisors The team slide is exceptionally strong for a Series B deck. It highlights Ran Ma (Biomedical Engineering, Johns Hopkins), Jie Fu (Manufacturing, Cisco/Philips), and Henk Jan Scholten (Global Textile Sourcing). The inclusion of logos from Johns Hopkins, Philips, and Cisco adds immediate institutional credibility. The advisor section is equally dense, featuring five medical and business experts, including a "Business Advisor" from Guitar Hero (Charles Huang), suggesting expertise in scaling consumer hardware.

Slide 12: The Future is Now This is the 'Platform' slide. It suggests that while they are starting with healthcare, the "Siren Eco-System" has applications in Fitness, Fashion, Military, and Entertainment. This is designed to expand the Total Addressable Market (TAM) in the eyes of an investor who might worry that diabetic socks are too niche.

Slide 13: Contact A simple closing slide with the website and contact email. It mirrors the branding of the opening slide, maintaining a consistent visual identity.

What Works in This Deck

High-Stakes Problem Framing: The deck does an excellent job of making the 'Diabetic Foot' seem like an urgent, solvable crisis. By linking neuropathy to a $17 billion cost, they make the investment case about cost-avoidance, which is a powerful motivator in healthcare. · Visual Simplicity: The deck avoids 'wall-of-text' slides. It uses large fonts and high-quality photography to convey one idea per slide. This is ideal for a presentation that is being talked through by a founder. · Credibility by Association: The team slide (Slide 11) is a masterclass in using logos to build trust. Even if an investor doesn't know the founders, they know Johns Hopkins and Philips.

What is Missing

The Business Model: There is no mention of how Siren Care actually makes money. Is it a one-time hardware sale? A monthly subscription for the monitoring service? A reimbursement play through insurance (CPT codes)? This is a major omission for a Series B deck. · Unit Economics: Investors at this stage want to know the Cost of Goods Sold (COGS) and the Customer Acquisition Cost (CAC). None of this is present. · Competition: The deck operates as if Siren Care is the only company in the world working on smart textiles or diabetic foot care. A slide acknowledging competitors (like Orpyx) would have shown market awareness. · The Ask: The deck ends without telling the investor what the company wants. There is no mention of the round size, the valuation, or the milestones they intend to hit with the new capital.

What a Founder Should Copy

The 'Progression' Slide: Slide 6 is a perfect way to illustrate a problem. If your product prevents a catastrophic outcome, show the steps leading to that catastrophe and place your product as the barrier. · Focusing on a Niche First: Even though Siren has a 'platform' technology (smart fabric), they spent 80% of the deck on one specific use case. Founders should copy this 'wedge' strategy—prove you can solve one big problem before claiming you can solve everything. · Quantifying the Macro-Pain: Using the $17B figure (Slide 7) gives the investor a sense of the 'prize' if the company succeeds. Always find the largest, most reputable number associated with the problem you are solving.

Frequently asked questions

What is the primary product described in the Siren Care deck?: The primary product is the Siren Smart Sock, a temperature-sensing wearable designed for diabetic patients. According to Slide 4 and Slide 9, these socks use proprietary smart fabric to monitor foot temperature continuously. This data is then transmitted to a mobile app to detect potential injuries or ulcers before they become severe, as shown on Slide 10.
How does Siren Care justify the market need for smart socks?: Siren Care justifies the need by highlighting the 'staggering financial costs' of diabetic foot complications, which Slide 7 states is $17 billion annually in the U.S. alone. Furthermore, Slide 6 illustrates a direct progression from neuropathy to ulcers and, ultimately, amputations, positioning the socks as a preventative tool that can reduce ulcers by 72% (Slide 8).
Who are the key members of the Siren Care leadership team?: The team is led by CEO Ran Ma, who has a background in Biomedical Engineering from Johns Hopkins University. Other key members include CTO Jie Fu (formerly of Cisco and Philips) and COO Henk Jan Scholten, who specializes in global textile sourcing. The team is supported by a robust board of medical and business advisors, as detailed on Slide 11.
What is missing from the Siren Care pitch deck?: The deck is notably missing several standard venture capital components. There are no slides detailing the business model (subscription vs. hardware sale), no financial projections, no competitive landscape analysis, and no specific 'Ask' regarding the amount of capital being raised or the intended use of funds.
Is Siren Care strictly a healthcare company according to the deck?: While the deck focuses almost entirely on the 'Diabetic Foot Program,' Slide 12 reveals a much broader vision. It describes a 'Siren Eco-System' where their smart textile technology could be applied to fitness, fashion, military, and entertainment sectors, suggesting the company views itself as a platform technology rather than a single-product medical device firm.

Cover slide of the Siren Care pitch deck — Series-B 2015 — Siren Care pitch deck, slide 1 (2015)

Siren Care pitch deck: the facts

Company: Siren Care
Year: 2015
Stage: Series-B
Slides: 13

Siren Care pitch deck PDF

The full Siren Care deck is embedded on this page and can be read slide by slide in the browser — no download or account required. Each slide is covered in the breakdown above.

What the Siren Care pitch deck was used for

This deck is a 13‑slide fundraising presentation from Siren Care, a company that uses embedded microsensors in fabric to create smart socks for continuous temperature monitoring of diabetic feet. The deck focuses on the high‑urgency problem of diabetic foot complications and positions Siren’s smart textiles as a medical device and remote patient monitoring solution for preventing diabetic foot ulcers. Based on the external funding history, the “nearly $21M Series B” closed in 2021 aligns with the $21.9M figure associated with this deck, suggesting it was used around that Series B raise led by Anathem Ventures with participation from DCM, Khosla Ventures, 500 Startups, Founders Fund and others. The pitch thus represents a later‑stage growth round aimed at commercial expansion, reimbursement coverage, and broader adoption of Siren’s diabetic foot monitoring platform.

Business model: Siren Care develops and sells remote patient monitoring solutions based on smart textiles, most notably temperature-sensing smart socks for people with diabetes to help prevent diabetic foot ulcers.

Round: Series B
Lead investor: Anathem Ventures
Investors: Anathem Ventures (lead)., DCM., Khosla Ventures., 500 Startups / 500 Global., Founders Fund., Manta Ray., Mighty Capital., Portfolia.
Headquarters: San Francisco, California, United States.
Industry: Medical devices / digital health / remote patient monitoring.

Year: 2020–2021, when the initial $11.8M Series B and subsequent $9M extension were announced and closed.

Raised: Siren first raised $11.8M in Series B funding and subsequently added a $9M extension, bringing the total Series B financing to nearly $21M according to the company; external coverage describes this as approximately $18M–$21M.

Total funding: Public sources report Siren Care’s total funding in the range of approximately $36M–$49M across multiple rounds, including a $3.4M early round, a $6.5M Series A, an $11.8M Series B plus a $9M Series B extension, and a later $9.5M strategic round; different databases list $36.6M, $40.35M, $40.55M, and $49.7M respectively.

Use of funds as presented: Commercial expansion of its smart‑fabric remote patient monitoring platform, including scaling production of smart socks, expanding clinical programs for diabetic foot ulcer prevention, and building out operations and market presence.

What happened after the Siren Care deck

Following the development of its temperature‑sensing smart socks for diabetics, Siren Care raised multiple rounds of venture and strategic capital, including an approximately $21M Series B used for commercial expansion and later a $9.5M round led by Mölnlycke Health Care; the company has since secured reimbursement coverage and continues to operate remote patient monitoring programs for diabetic f

Raised around $3.4M in an early investment round to launch smart socks for diabetic monitoring.
Raised a previously undisclosed approximately $6.5M Series A in 2018 to further product development and commercializatio
Closed an $11.8M Series B led by Anathem Ventures with participation from DCM, Khosla Ventures, 500 Startups, and Founde
Secured a $9.5M strategic funding round in 2025 led by an $8M investment from Mölnlycke Health Care to advance diabetic
Achieved coverage for Siren Socks under Medicare, Medicare Advantage, and many private insurance plans, integrating the

What the Siren Care deck got right

Clear focus on a high‑urgency diabetic complication. Siren Care addresses a **specific, high‑stakes medical problem**—diabetic foot ulcers and amputations—by focusing its deck narrative on the “diabetic foot,” which converts a generic sensor‑textile technology into a concrete, urgent healthcare solution for a large population of patients with diabetes.
Differentiated smart‑textile approach and user‑friendly form factor. The company’s core technology embeds microsensors directly into fabric to create **washable, affordable smart socks** that continuously monitor foot temperature, allowing for unobtrusive remote patient monitoring compared with bulkier or less user‑friendly devices.
Validated by a strong, well‑known investor syndicate. External funding history shows that around the time of this deck, Siren Care successfully secured a substantial Series B round approaching $21M from a high‑quality investor syndicate including Anathem Ventures, Khosla Ventures, DCM, Founders Fund, 500 Startups, and later additional investors; this validates the deck’s ability to communicate the opportunity to sophisticated capital providers.
Compelling path to reimbursed remote patient monitoring. Subsequent developments demonstrate that Siren translated its solution into **reimbursed remote patient monitoring programs**, with Medicare, Medicare Advantage, and private insurers covering Siren Socks, indicating that the underlying business model and clinical value proposition described in the deck were robust enough to gain payer traction.
Concise and focused narrative connecting technology to need. The lean, 13‑slide format keeps the story focused on the link between smart textiles and a massive, underserved medical need, making it easier for investors to quickly understand the product, the target population, and the potential impact without distraction.
Strong alignment with clinical outcomes and cost avoidance. By centering on prevention of ulcers rather than purely diagnostic monitoring, the deck’s problem‑solution framing inherently speaks to **cost savings and limb‑saving outcomes**, which resonate with providers and payers and support a strong health‑economic argument.

What could have been stronger

Limited visibility into quantitative clinical and economic traction in the deck. The deck is described as only 13 slides and focused on the diabetic foot problem and smart textiles solution, with no externally visible indication that it includes detailed historical financials, unit economics, or cohort‑level outcomes; given the company’s later emphasis on reimbursement (Medicare coverage) and clinical performance, the absence of clearly documented metrics in this deck would leave investors with limited quantitative evidence of efficacy and economic value at the time.
Reimbursement and regulatory strategy may be under‑developed in the deck. While Siren Care later secured Medicare and private insurance coverage for its socks and built out remote patient monitoring programs, there is no evidence that this 2015–2021‑era deck presented a clear reimbursement and regulatory pathway beyond the immediate product concept, potentially leaving questions about regulatory classification, clinical validation requirements, and long‑term payer strategy.
Long‑term smart‑textile platform narrative appears narrow. External sources emphasize that Siren expanded into broader remote patient monitoring and strategic partnerships (e.g., Mölnlycke and European distribution), but the lean deck’s focus on a single acute use case (diabetic foot) may not have fully articulated the longer‑term platform vision for smart textiles across multiple conditions and care pathways, limiting perceived upside for some investors.
Competitive differentiation against other digital health solutions is not fully evidenced. Given that Siren operates in a crowded digital health and RPM landscape, with many sensor‑ and wearable‑based solutions, the deck’s emphasis on smart socks and diabetic foot may not clearly differentiate competitive positioning versus other monitoring technologies (e.g., continuous glucose monitoring, other foot‑care devices) in terms of clinical outcomes, workflow integration, and cost‑effectiveness.
Execution and operational scalability not deeply substantiated in the deck. Public information shows that Siren has operations connected to San Francisco and Denmark and later global ambitions; a brief 13‑slide deck focused on a single problem and raise likely devotes limited space to organizational capabilities, manufacturing scalability, and risk management, leaving investors to infer execution capacity rather than seeing it substantiated.

How an investor would read this deck

What draws attention

High‑urgency **diabetic foot ulcer prevention** problem with clear clinical and economic consequences (amputations, hospitalizations, costs), making the value proposition intuitively compelling for payers and providers.
Proprietary **smart textile platform** embedding microsensors directly into fabric, enabling continuous monitoring via everyday garments (socks) rather than more intrusive devices.
Evidence of strong **investor syndicate** and follow‑on capital around the Series B (Anathem Ventures, Khosla Ventures, DCM, Founders Fund, 500 Startups, and later strategic investors like Mölnlycke), suggesting significant market confidence.
Emerging **reimbursement coverage** (Medicare, Medicare Advantage, private plans) and remote patient monitoring positioning in later years, indicating a path to scalable, recurring revenue from clinical programs.

Risks that stand out

Regulatory and reimbursement risk: success depends on sustained coverage and favorable reimbursement for diabetic foot monitoring and RPM; changes in payer policies or regulatory requirements could impact adoption and economics.
Clinical validation risk: while the concept of temperature monitoring for ulcers is clinically grounded, insufficient or inconclusive trial data at scale could limit provider adoption and payer support.
Competitive risk: other digital health and sensor‑based solutions targeting diabetic complications and chronic disease management may offer alternative approaches, potentially eroding Siren’s share if differentiation is not clear.
Manufacturing and scalability risk: embedding microsensors in fabric at scale while maintaining reliability, washability, and cost‑effectiveness is non‑trivial and could pose quality or margin challenges.
Strategic partnership concentration: later expansion relies in part on strategic partners (e.g., Mölnlycke for European markets); dependence on a small number of partners could create distribution or negotiation risk.

Questions this deck invites

What specific clinical trial or real‑world evidence did Siren have at the time of this deck to demonstrate that temperature‑monitoring socks reduce diabetic foot ulcer incidence, hospitalizations, or amputations, and how robust were those s
How was the regulatory pathway defined for Siren’s smart socks and RPM solution (e.g., medical device classification, software as a medical device, approvals or clearances), and what milestones had already been achieved by the time of the S
What were the detailed unit economics and reimbursement mechanics for Siren’s offering at that stage: device cost, monitoring fees, payer mix, margins, and program‑level ROI for providers and payers?
How defensible is Siren’s smart‑textile IP (patents, know‑how) against larger device or apparel manufacturers, and what barriers exist to competitors introducing similar sensor‑embedded garments?
What was the go‑to‑market strategy and sales motion for securing hospital systems, podiatry practices, and payers, and how did Siren plan to scale beyond initial diabetic foot programs into broader RPM use cases?

What founders can take from the Siren Care deck

Anchoring a broad enabling technology (smart textiles) in a **single, urgent clinical use case** like diabetic foot ulcer prevention can make an otherwise abstract platform immediately concrete and investable.
Demonstrating a path from early rounds to a **sizable Series B with strong investors** shows how cumulative traction and validation can culminate in a larger growth financing, which can be highlighted in a later‑stage deck.
Positioning a hardware‑plus‑software product as part of **remote patient monitoring programs with reimbursement** allows a deck to speak in terms of recurring revenue and payer‑aligned value rather than one‑off device sales.
Articulating a clear **clinical and economic narrative**—linking ulcer prevention to avoided amputations, reduced hospitalizations, and cost savings—helps bridge the gap between novel technology and healthcare decision‑makers’ priorities.
Showcasing **strategic investor involvement** (e.g., Mölnlycke’s later investment and distribution support) underscores the importance of aligning with established industry players to accelerate adoption, which a deck can frame as validation and distribution leverage.
Maintaining a **lean deck** that focuses on a specific problem‑solution pair can be powerful for clarity, but later‑stage decks benefit from layering in measured detail on clinical data, reimbursement, and scalability to satisfy institutional investor diligence.

Siren Care pitch deck: common questions

What does Siren Care do?

Siren Care is a medical device and digital health company that embeds microsensors in fabric to create smart textiles, most notably temperature‑sensing smart socks that continuously monitor the feet of people with diabetes to detect early signs of diabetic foot ulcers and related complications.

Which fundraise is this Siren Care deck most likely associated with?

Siren Care’s most visible funding milestone tied to a roughly $21M raise is its Series B financing, where it first announced $11.8M led by Anathem Ventures with participation from DCM, Khosla Ventures, 500 Startups and Founders Fund, followed by a $9M extension that brought the total Series B to nearly $21M. This combined Series B amount corresponds closely to the $21.9M figure associated with the deck, though individual sources cite slightly different totals.

Who invested in Siren Care’s Series B round around $21M?

According to Siren’s own announcements and later coverage, investors in the approximately $21M Series B include Anathem Ventures as lead, with participation from existing backers such as DCM, Khosla Ventures, 500 Startups and Peter Thiel’s Founders Fund, plus additional investors including Manta Ray, Mighty Capital, Portfolia, and David Helgason in the extension.

What medical need does Siren Care’s product address?

The deck emphasizes the “diabetic foot” as a high‑urgency medical problem; externally, Siren’s product is used for early detection and prevention of diabetic foot ulcers by continuously monitoring foot temperature via smart socks and transmitting data to clinicians for remote patient monitoring.

How much funding has Siren Care raised overall and what are its key rounds?

Public databases and press reports indicate that Siren Care has raised multiple rounds, including a $3.4M early round, a $6.5M Series A, an $11.8M Series B plus a $9M Series B extension, and a later $9.5M strategic round led by Mölnlycke Health Care, with total funding reported between about $36M and nearly $50M depending on the source.